Navigation Links
Point-of-Delivery Drug. Reconstitution Systems Markets, Strategies and Prospects
Date:3/14/2013

DUBLIN, Ireland, March 14, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "Point-of-Delivery Drug. Reconstitution Systems Markets, Strategies and Prospects" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Growth in the number of injectable drugs supplied in solid form for reconstitution prior to administration is being driven by the increase in drugs based on biological NCEs. These drugs are typically unstable at ambient temperatures and to preserve their shelf life must be either stored at low temperature (the so-call 'cold chain') or processed into a form that will preserve their pharmacological efficacy until they reach their therapeutic destination.

Because the cost of transporting and storing drugs using refrigeration is expensive and requires constant temperature monitoring to insure that the drug has not been exposed to environmental conditions that render unsafe for use as a therapeutic product, technologies such as lyophilization are becoming more prevalent.

The packaging and technologies developed and marketed for safe and reliable reconstitution at the point of administration are benefiting from this market trend. This report examines commercial drug reconstitution devices and systems and their impact on the injectable drug delivery sector.


Highlights

- Analyzes therapeutic demand drivers and evaluates the market impact and potential of commercial drug reconstitution systems

- Provides analysis of injectable drugs for reconstitution and assesses key market segments, market dynamics and market demographics

- Forecasts Injectable drug product demand by indication and therapy to 2017

-Profiles reconstitution system suppliers, their product activities, business strategies, and corporate alliances and affiliations

Topics Covered

Executive Summary

Market Dynamics

What's Driving the Growth in Engineered Reconstitution Systems?

Drug Reconstitution Systems - Commercial Devices

Drug Reconstitution - Therapeutic Sector Analysis

Market Factors

Drug Reconstitution Systems - Company Profiles

For more information and a full list of topics covered visit http://www.researchandmarkets.com/research/8qmbbz/pointofdelivery

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood , Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Drug Delivery



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. At RSNA, DR Systems Will Exhibit RIS, Reporting, Peer Review Systems
2. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
3. Dicom Systems and USARAD.com Announce Partnership and Introduce Beta Version of XMRI.com, New System by USARAD.com
4. BioPower Systems Awarded $5 Million from Victorian Government
5. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
6. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
7. CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems
8. MarketsandMarkets: Global Clinical Trial Management Systems Market Worth $1300.4 Million by 2016
9. A new class of electron interactions in quantum systems
10. AMPAC Fine Chemicals Continues to Invest in Quality Systems
11. Chemring Detection Systems Awarded $500k for Strategic Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology:
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):